Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Landos Biopharma, Inc. - Common Stock (NQ: LABP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Landos Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
From Kahn Swick & Foti, LLC
Via Business Wire
LABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024
LABP stock results show that Landos Biopharma missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
From Brodsky & Smith LLC
Via GlobeNewswire
Recap: Landos Biopharma Q4 Earnings
Via Benzinga
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP
From Kahn Swick & Foti, LLC
Via Business Wire
Nasdaq Turns Higher; Akanda Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Is the Stock Market Closed on Good Friday 2024?
Investors are wondering if the stock market is closed on Good Friday 2024 as they prepare for the upcoming Easter weekend. 
Via InvestorPlace
Landos Biopharma: Q3 Earnings Insights
Via Benzinga
Recap: Landos Biopharma Q1 Earnings
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
Landos Biopharma stock is up on Monday as LABP investors learn about a massive acquisition deal with AbbVie that values it at $137.5 million. 
Via InvestorPlace
Crude Oil Moves Higher; US New Home Sales Fall In February
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
From Brodsky & Smith LLC
Via GlobeNewswire
US Stocks Down; Chicago Fed National Activity Index Rises In February
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
LABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023
LABP stock results show that Landos Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Landos Biopharma - Investor Like It Better Than Analysts
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
From Landos Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.